| DEAR VALUED SUBSCRIBERS, |
Our brand new pick for tonight is CIHN!
CIHN is a MONSTER waiting to be awoken! Trading at just under nickle and with chart ready to move up, we feel the time is NOW to jump in!
CIHN is the holding company for their subsidiary Regenerative BioScience, Inc.
RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic.
The company's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies for degenerative diseases such as:
· MS
· Arthritis
· Degenerative Heart Diseases
· Diabetes
· Plus a host of experimental therapies in the brain trauma disease sector including CTE (Chronic traumatic encephalopathy)
CIHN is working on REAL products that show REAL results. The market here IS IN THE MULTI BILLIONS!!
CIHN Announces Site of 2nd International Treatment Facility; Facility is Approved!
Caribbean International Holdings (Pink Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc., ("RBS") previously announced on May 7, 2014, that it was opening new treatment locations in Guadalajara, Mexico, and Cabo St Lucas; In an update today, it was announced that the location in Guadalajara was the prestigious San Javier Hospital - Guadalajara. This will be the Company's second location that will offer stem cell therapies, in addition to its facilities in the Dominican Republic.
The hospital houses some of the most accomplished researchers/therapists in the stem cell field.
The Company plans to add other locations for its stem cell therapies/services, in order to give the patients more geographic options to choose from.
Dr. Gonzalez stated: "In a quest to offer patients better services and options, Regenerative BioScience is identifying key locations that patients can travel to and obtain excellent stem cell therapy care. One of those locations we have established lies in the beautiful, historical city of Guadalajara, Mexico. We are finalizing negotiations with the private state of the art Hospital San Javier in Guadalajara, Mexico." (http://www.sanjavier.com.mx/en/)
Dr. Gonzalez went on to say: "Most importantly, the Hospital San Javier is approved for stem cell therapies by the FDA equivalent in Mexico, Comisión Federal Para la Protección de los Riesgos Sanitarios (COFEPRIS). We are finalizing our medical staff, which will bring you the patient quality, caring and excellent service in a secure and ideal setting."
Steven Swank, Chairman and CEO of Caribbean International Holdings, stated, "We are finalizing our medical staff, which will bring our patients a superior level of quality, caring and excellent service in a secure and ideal setting as part of our goal to make our stem cell therapies a comfortable experience. We also want to make sure that our patients have options for their therapy. This location in Guadalajara is ideal and it's a great city to visit following their therapy. We will soon be naming our medical director for this facility, which will assure that our patients obtain excellent quality care, but we are not done. Regenerative Biosciences will soon add other locations for stem cell therapy in order to give the patient even more geographic options to choose from."
Regenerative Bioscience’s physicians treat patients with ex-vivo generated autologous Angiogenic Cell Precursors (ACP’s), which are derived from the patient’s own bone marrow aspirate taken from the pelvic bone using modern techniques which allow for patient comfort. These adult stem cells are capable of promoting the formation of new vascularization and viable tissue. The mononuclear cells are isolated and concentrated at the same location as the treatment.
A heart patient’s own adult stem cells are then injected into the coronary vessels and directly into the walls of the myocardium using a specialized catheter. Stem cells are introduced into the pulmonary arteries of lung patients using a catheter. These procedures are similar to a balloon angioplasty and carry similar risks. For patients with peripheral artery disease, stem cells are injected directly into the muscle of the affected limb using a syringe.
The process consists of four periods:
Screening:
This period begins with a complimentary evaluation of the patient’s medical records. It consists of the evaluation of his / her eligibility for the treatment according to the inclusion / exclusion criteria established by the treating physicians. After initial assessment of a patient’s eligibility for the treatment, he / she will sign an informed consent form and thus formally be considered for treatment.
Treatment:
This period starts with the patient being admitted to the treatment facility. Certain clinical and laboratory tests may be performed just prior to the administration of the adult stem cells. Heart and lung patients will be brought to a cardiac catheterization laboratory. Angiography will be performed to define the artery or arteries planned to be used for the cell injection. The administration will be performed by a balloon catheter after blocking the injected artery proximally by inflating the balloon and / or by intra-myocardial injection using a specialized catheter delivery system. The protocol maximizes stem cell contact time and delivery to the myocardial tissue. Proportion of cells and mode of delivery methods will vary based on the individual patient’s clinical and anatomical presentation.
Primary Acute Safety Follow-Up:
Immediately after the treatment and for at least 48 hours after treatment, safety parameters will be intensively and closely monitored. Acute monitoring will be performed after the administration of the adult stem cells, during the patient’s stay in the recovery room and will include monitoring of cardiac rhythm, core temperature, heart rate, systolic and diastolic blood pressure, oxygen saturation, ECG and other recovery room monitoring parameters. Heart and lung patients stay overnight in the hospital for observation. On the day after treatment the patient may be released to their local hotel for another day of rest and observation prior to returning home.
Secondary Chronic Follow-Up:
Upon returning home, patients will continue to be monitored and evaluated according to the established routine for such cases. Patients are asked to continue to see their own physician and send copies of any diagnostic tests to us in order for Regenerative Bioscience to monitor the benefits received from the treatment.
The Method Used For Concentrating Adult Stem Cells
The method used for concentrating adult stem cells has a direct impact on the stem cells. In order to deliver enough progenitor cells, the stem cells not only need to be concentrated but concentrated in such a way as to leave them viable and functional. Stem cells concentrated using our unique closed system meet these critical criteria.
Our exclusive processes ensure a consistent and reproducible end product.
|
|
|
|
|
|
.
WE ARE NOT REGISTERED BROKER DEALERS OR REGISTERED INVESTMENT ADVISORS, AND ARE NOT QUALIFIED TO GIVE FINANCIAL ADVICE. This site, www.pennystocklaboratory.com, is property of and operated by Eden Media Group, LLC. Www.pennystocklaboratory.com is a financial information and marketing firm which provides paid advertising services for our clients to generate exposure of the featured companies. Www.pennystocklaboratory.com nor its owners, employees, affiliates and agents responsible for the content of this site are not registered as Broker Dealers, Investment Advisors or financial analysts in any jurisdiction whatsoever, nor are they members of any association for research providers. We are not qualified to give financial advice to anyone.
WE MAY BE PAID TO PUBLISH THE INFORMATION POSTED TO THE SITE AND SENT TO YOU BY EMAIL, WHICH IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IS NOT INVESTMENT ADVICE. The content of our site and our e-mail alerts is advertising used to generate exposure of certain featured companies and does not purport to provide an analysis of the companies’ financial position, operations or prospects,. In certain cases, Www.pennystocklaboratory.com is paid a fee for such services, which is disclosed at the bottom of this disclaimer [HYPERLINK]. Our analysis is provided solely for informational purposes, and should not be construed as a recommendation or solicitation to buy or sell any security.
BY FEATURING A COMPANY’S STOCK, WE ARE NOT RECOMMENDING THAT YOU PURCHASE OR SELL THAT COMPANY’S SECURITIES, WHICH ARE HIGHLY SPECULATIVE. The stocks featured on our site and in our emails are classified as “micro-cap” securities, and investment in these securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of these investments. Investors use of the information provided by Www.pennystocklaboratory.com is at the investor’s sole risk, which may result in the loss of some or all of an investor’s entire investment. Www.pennystocklaboratory.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Www.pennystocklaboratory.com. Do not listen to what we say, do your own research.
RELEASE OF LIABILITY. Through use of this site or our email list, you agree that you are of at least 18 years of age, and that you shall hold harmless Www.pennystocklaboratory.com, its owners, officers, employees, agents and representatives, and to completely release them, from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur through your use or reliance upon the information provided by or through Www.pennystocklaboratory.com.
SAFE HARBOR STATEMENT, FORWARD-LOOKING STATEMENTS. Investing in securities is speculative and carries risk, and past performance does not guarantee future results. You should never invest in any stock featured on our site or in our emails unless you can afford to lose your entire investment.
THIRD PARTY WEBSITES AND INFORMATION. This site and email you receive may provide hyperlinks to third party websites or access to third party content. Www.pennystocklaboratory.com does not control, endorse, or guarantee content found in such sites. You agree that Www.pennystocklaboratory.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that Www.pennystocklaboratory.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
DISCLOSURE OF FEES. Www.pennystocklaboratory.com has been paid the following fees in consideration of featuring certain companies on the site and in email alerts:
FOR A FULL DISCLAIMER, PLEASE VISIT http://www.pennystocklaboratory.com/disclaimer.php
Please be advised Www.pennystocklaboratory.com has been compensated up to $2,500 for this email via a Non-Affiliated Third Party
|
